This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Antonio Colombo, MD; John Cosgrave, MD

JAMA. 2005;294:1268-1270.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Percutaneous coronary interventions (PCIs) have become the dominant form of revascularization. This evolution has been based on the results of a large number of pivotal randomized trials. Since the pioneering work of Gruntzig,¹ 2 major developments have revolutionized clinical cardiology practice. The first was the introduction of bare metal stents by Sigwart and Puel in 1986 and results following use of stents to treat impending or acute vessel closure after balloon angioplasty were subsequently reported in 1987.² Stent implantation improved both acute and long-term results following angioplasty, but perhaps more important from the patient’s perspective, dramatically reduced the need for emergency coronary artery bypass graft (CABG) surgery.

The second development was the advent of drug-eluting stents in an effort to prevent a need for repeat revascularization due to restenosis. Multiple studies comparing PCI with CABG surgery have shown that the superiority of CABG surgery . . . [Full Text of this Article]

Author Affiliations: Department of Cardiology, Columbus and San Raffaele Hospitals, Milan, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial
, , , , , , , , , , , , and
JAMA. ;294():1215-1223.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
Grube et al.
Eur Heart J 2007;28:2578-2582.
ABSTRACT | FULL TEXT  

Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
Cosgrave et al.
J Am Coll Cardiol 2007;49:2320-2328.
ABSTRACT | FULL TEXT  

Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents: Pooled Analysis of Five Clinical Trials
Kereiakes et al.
J Am Coll Cardiol 2006;48:21-31.
ABSTRACT | FULL TEXT  

Role of drug eluting stents in diabetic patients
Boccara et al.
Heart 2006;92:579-581.
ABSTRACT | FULL TEXT  

Raising the Bar for Paclitaxel-Eluting Stents
Journal Watch Cardiology 2005;2005:3-3.
FULL TEXT